Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-CHRNA5 Recombinant Antibody (CBYY-C3166) (CBMAB-C4609-YY)

Online Inquiry
Published Data

Summary

Host Animal
Mouse
Specificity
Human, Rat
Clone
CBYY-C3166
Antibody Isotype
IgG2a
Application
ELISA, WB, FC

Basic Information

Immunogen
Purified recombinant fragment of human Nicotinic Acetylcholine R alpha 5/CHRNA5 (AA 23-254).
Host Species
Mouse
Specificity
Human, Rat
Antibody Isotype
IgG2a
Clonality
Monoclonal Antibody
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500
ELISA1:100-1:1,000
IHC-P1:50-1:500
WB1:100-1:2,000
ELISA1:100-1:2,000
FC1:10-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS
Preservative
0.05% sodium azide
Concentration
1 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cholinergic Receptor Nicotinic Alpha 5 Subunit
Entrez Gene ID
Human1138
Mouse110835
Pig100156023
UniProt ID
Alternative Names
AHUS5, ARMD9, ASPa, C3b, CPAMD1, HEL-S-62p, C3
Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Biological Process
Behavioral response to nicotine Source: UniProtKB
Chemical synaptic transmission Source: GO_Central
Ion transmembrane transport Source: GO_Central
Nervous system process Source: GO_Central
Regulation of membrane potential Source: GO_Central
Regulation of synaptic vesicle exocytosis Source: Ensembl
Response to nicotine Source: GO_Central
Signal transduction Source: GO_Central
Synaptic transmission, cholinergic Source: GO_Central
Cellular Location
Postsynaptic cell membrane; Cell membrane
Topology
Extracellular: 23-254
Helical: 255-275
Helical: 282-302
Helical: 317-337
Cytoplasmic: 338-429
Helical: 430-451
Extracellular: 452-468
More Infomation

Forget, B., Icick, R., Robert, J., Correia, C., Prevost, M. S., Gielen, M., ... & Maskos, U. (2021). Alterations in nicotinic receptor alpha5 subunit gene differentially impact early and later stages of cocaine addiction: a translational study in transgenic rats and patients. Progress in Neurobiology, 197, 101898.

Brynildsen, J. K., & Blendy, J. A. (2021). Linking the CHRNA5 SNP to drug abuse liability: From circuitry to cellular mechanisms. Neuropharmacology, 186, 108480.

Chen, L. S., Baker, T. B., Miller, J. P., Bray, M., Smock, N., Chen, J., ... & Bierut, L. J. (2020). Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a randomized placebo‐controlled trial. Clinical Pharmacology & Therapeutics, 108(6), 1315-1325.

Venkatesan, S., & Lambe, E. K. (2020). Chrna5 is essential for a rapid and protected response to optogenetic release of endogenous acetylcholine in prefrontal cortex. Journal of Neuroscience, 40(38), 7255-7268.

Tam, A., Obeidat, M., Hackett, T. L., Dorscheid, D. R., Singhera, G., Hogg, J. C., & Sin, D. D. (2019). Cholinergic Receptor Nicotinic Alpha 5 Expression in the Airways of Patients with Chronic Obstructive Pulmonary Disease. In B64. COPD: MECHANISM AND TREATMENT (pp. A3845-A3845). American Thoracic Society.

Lin, C. H., Lee, H. H., Kuei, C. H., Lin, H. Y., Lu, L. S., Lee, F. P., ... & Lin, Y. F. (2019). Nicotinic acetylcholine receptor subunit Alpha-5 promotes radioresistance via recruiting E2F activity in oral squamous cell carcinoma. Journal of clinical medicine, 8(9), 1454.

Tomaz, P. R. X., Santos, J. R., Scholz, J., Abe, T. O., Gaya, P. V., Negrão, A. B., ... & Santos, P. C. J. L. (2018). Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women. BMC medical genetics, 19(1), 1-8.

Cingir Koker, S., Jahja, E., Shehwana, H., Keskus, A. G., & Konu, O. (2018). Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) RNAi is associated with cell cycle inhibition, apoptosis, DNA damage response and drug sensitivity in breast cancer. PloS one, 13(12), e0208982.

Köker, Ş. C. (2018). Effects of Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) RNAi on apoptosis, DNA damage response, drug sensitivity, and HSA-MIR-495-3P overexpression in breast cancer (Doctoral dissertation, Bilkent University).

Morton, G., Nasirova, N., Sparks, D. W., Brodsky, M., Sivakumaran, S., Lambe, E. K., & Turner, E. E. (2018). Chrna5-expressing neurons in the interpeduncular nucleus mediate aversion primed by prior stimulation or nicotine exposure. Journal of Neuroscience, 38(31), 6900-6920.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-CHRNA5 Recombinant Antibody (CBYY-C3166)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Online Inquiry